NorthX Biologics

NorthX Biologics operates as a contract development and manufacturing organization (CDMO), positioning itself as a key partner for the biopharmaceutical and biotech sectors. The company's facilities, with a heritage in Good Manufacturing Practice (GMP) since 1992, were formally established as NorthX Biologics in October 2021. Headquartered in Matfors, Sweden, with a second site in Stockholm, the company leverages decades of operational experience inherited from predecessors like Cobra Biologics. In July 2023, NorthX acquired the biologics manufacturing unit from Valneva, a strategic move that expanded its capabilities, particularly in mammalian expression systems and viral vectors.

The company is led by CEO Dr. Janet Hoogstraate, who joined in August 2023 after serving as managing director of Valneva Sweden. Her background includes a Ph.D. in Biopharmaceutical Sciences and extensive experience in the pharmaceutical industry since 1995. The business model is centered on providing end-to-end services for biopharmaceutical companies, from early-stage research and development projects to large-scale commercial GMP manufacturing. Its clientele ranges from small biotechs and academic groups lacking their own manufacturing capacity to larger pharmaceutical companies needing to outsource specific projects. NorthX generates revenue by offering this comprehensive suite of services. The company is privately held and venture capital-backed, with investors including Flerie and Signet Healthcare Partners. A May 2025 investment from Signet aims to accelerate facility expansion and U.S. commercial reach.

NorthX Biologics provides a wide spectrum of services for advanced biologics. This includes process development, analytics, and GMP manufacturing for modalities such as plasmid DNA (pDNA), mRNA, recombinant proteins, cell and gene therapies, viral vectors, and extracellular vesicles. For instance, they offer a full suite of services for cell therapy product development and are equipped to produce plasmid DNA for applications like DNA vaccines and viral vector gene therapies. The company operates two main facilities in Sweden, equipped for both microbial and mammalian production, and provides aseptic fill-finish services. A significant milestone was the 2021 recognition by the Swedish government as a national innovation hub for advanced biologics, which led to the creation of its "Innovation Hub" to support emerging therapies. This hub allows clients to access cutting-edge technology for development without requiring heavy initial investments.

Keywords: biologics CDMO, contract manufacturing, gene therapy, cell therapy, plasmid DNA manufacturing, recombinant proteins, viral vectors, GMP manufacturing, biopharmaceutical services, process development, aseptic fill-finish, mRNA production, drug development partner, life sciences, biotech manufacturing, advanced biologics, pharmaceutical services, microbial production, mammalian production, clinical trial manufacturing